Search results
Results from the WOW.Com Content Network
Harish Chandra Verma (born 3 April 1952), popularly known as HCV, is an Indian experimental physicist, author and emeritus professor of the Indian Institute of Technology Kanpur. In 2021, he was awarded the Padma Shri , the fourth highest civilian award, by the Government of India for his contribution to Physics Education. [ 1 ]
The inclusion of the term ‘area of forest’ provide clarity that there may be instances where an HCVF zone might be restricted to part of a forest, while the FSC definition implied that the presence of one or more HCV attribute would render the whole forest as to be a ‘high conservation value forest’.
Download as PDF; Printable version; ... (HCV). This two-part program was announced in 2003 and continued into 2006. ... The HTV-2 was the last active part of the ...
NS2-3 protease (of hepatitis C virus, HCV) is an enzyme responsible for proteolytic cleavage between NS2 and NS3, which are non-structural proteins that form part of the HCV virus particle. NS3 protease of hepatitis C virus, on the other hand, is responsible for the cleavage of non-structural protein downstream.
HCV is a positive-sense single-stranded RNA virus that has been demonstrated to replicate in the hepatocytes of both humans and chimpanzees. A single HCV polyprotein is translated, and then cleaved by cellular and viral proteases into three structural proteins (core, E1, and E2) and seven nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B).
HCV genome. E1 is one of two subunits of the envelope glycoprotein [1] found in the hepatitis C virus. [2] [3] The other subunit is E2.This protein is a type 1 transmembrane protein with a highly glycosylated N-terminal ectodomain and a C-terminal hydrophobic anchor.
Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. [2] [3] It binds to the HCV nonstructural protein 3 active site. [4] It was initially developed by Schering-Plough, [5] then by Merck after it acquired Schering in 2009. It was approved by the FDA in May 2011. [6]
According to this report, the device detected hepatitis C with high specificity and sensitivity. [2] The device was said to compare the received electromagnetic signal from a patient to the ideal signal emitted by a specific part of the HCV RNA genome that had been measured in a laboratory and stored on the device. If those signals agreed, the ...